Corpus overview


Overview

MeSH Disease

Human Phenotype

There are no HP terms in the subcorpus


Transmission

Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Early Safety Indicators of COVID-19 ConvalescentPlasma in 5,000 Patients

    Authors: Michael Joyner; R. Scott Wright; DeLisa Fairweather; Jonathon Senefeld; Katelyn Bruno; Stephen Klassen; Rickey Carter; Allan Klompas; Chad Wiggins; John RA Shepherd; Robert Rea; Emily Whelan; Andrew Clayburn; Matthew Spiegel; Patrick Johnson; Elizabeth Lesser; Sarah Baker; Kathryn Larson; Juan Ripoll Sanz; Kylie Andersen; David Hodge; Katie Kunze; Matthew Buras; Matthew Vogt; Vitaly Herasevich; Joshua Dennis; Riley Regimbal; Philippe Bauer; Janis Blair; Camille van Buskirk; Jeffrey Winters; James Stubbs; Nigel Paneth; Arturo Casadevall

    doi:10.1101/2020.05.12.20099879 Date: 2020-05-14 Source: medRxiv

    Background: Convalescent plasma SERO is the only antibody SERO based therapy currently available for COVID-19 patients. It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma SERO has not yet been shown to be safe as a treatment for COVID-19. Methods: Thus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma SERO in 5,000 hospitalized adults TRANS with severe or life threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma SERO. Results: The incidence of all serious adverse events (SAEs) in the first four hours after transfusion was <1%, including mortality rate (0.3%). Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality (n=4), transfusion-associated circulatory overload (TACO; n=7), transfusion-related acute lung injury MESHD (TRALI; n=11), and severe allergic transfusion reactions MESHD (n=3). However, only 2 (of 36) SAEs were judged as definitely related to the convalescent plasma SERO transfusion by the treating physician. The seven-day mortality rate was 14.9%. Conclusion: Given the deadly nature of COVID-19 and the large population of critically-ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma SERO is safe in hospitalized patients with COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.